Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 15, 2026 · Filed Oct 20, 2026
The CEO of Biocardia paid $190 out of pocket for Biocardia shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$190
Shares × reported transaction price
<$25K
+0.1%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 1 month
Confirmed open-market purchases by the same insider in the available history
No
Compared with 57 earlier confirmed purchases
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
64 days after results of Aug 12, 2026, 28 days before results of Nov 12, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $0.9385 on Oct 15, 2026, 22% above its 52-week low and 37% below its high, after a 15% drop over the previous 30 trading days
52-week range $0.7711 (Jul 30, 2026) to $1.49 (Oct 21, 2025), 23% of the way up, from 251 adjusted closes. 30 trading days earlier: $1.11 on Sep 2, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −3.6% | −0.1% | −3.5% |
Past results only. Not a forecast.
Insider buying
Traded Oct 16 · filed 4 days later
The CEO of Biocardia paid $285 out of pocket for Biocardia shares.
Insider buying
Traded Sep 29 · filed 1 day later
The CEO of Biocardia paid $1K out of pocket for Biocardia shares.
Insider buying
Traded Sep 23 · filed 1 day later
The CEO of Biocardia paid $2K out of pocket for Biocardia shares.
Peter Altman, President and CEO's past purchases, 90 days after disclosure: 38 buys, median −9.0 pts vs S&P 500, beat it 13 of 38 times. Past results, not a forecast.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.